Raffles Medical Group

Raffles Medical Group: SCB maintains Buy and raises its TP to $4.25 after the grp’s 1Q13 results. The key takeaway from the results briefing is mgt’s strategic decision to pursue hospital projects in China. House optimistic that Raffles will proceed with the new hospital in Shekou, China, and that there is potential for additional hospital projects in the future. ontinue to like Raffles for its steady growth, strong balance sheet and robust cash flow generation.